Dolutegravir/Lamivudine Provide HIV Suppression Through 3-Year TANGO Findings
The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.
New 3-year findings presented at IDWeek 2021 show combination therapy dolutegravir/lamivudine (Dovato) was associated with high efficacy non-inferior to 3- or 4-drug tenofovir alafenamide (TAF)-based regimens for HIV viral suppression.
The 144-week findings from ViiV Healthcare’s TANGO trial support long-term efficacy of switching people living with HIV from a TAF regimen to the 2-dose option.
Presented by Olayemi Osiyemi, MD, President of Triple O Research Institute in West Palm Beach, the TANGO trial showed non-inferior efficacy of dolutegravir/lamivudine to TAF-based 3- or 4-drug regimens, with no confirmed virologic withdrawals in treated participants and a favorable tolerability and safety profile of patients receiving the 2-drug regimen.
In an interview with Contagion during IDWeek, Osiyemi reviewed the trial data, and discussed the value of interpreting long-term efficacy and safety for HIV virologic suppression with regimens that require fewer drugs for patients.
“I guess you have to have the right marriage—the right 2 drugs to make it work,” Osiyemi said. “If we can use the fewest number of drugs, we can eliminate long-term toxicity and drug costs.”
